Clinical Trial

FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis

Name: FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis — clinical trial record (NCT06988852)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

Try FOLFOX-HAIC combining bevacizumab or cetuximab for initially unresectable colorectal liver metastasis patients to increase the conversion to resection rate to improve long-term survival outcomes

Trial Details

NCT Number	NCT06988852
Lead Sponsor	Tongji Hospital
Conditions	Colorectal Liver Metastasis (CRLM)
Enrollment	300 participants
Start Date	2023-05-01
Primary Completion	2030-12-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-05-25